Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal
Overview
- Phase
- Phase 2
- Intervention
- resveratrol
- Conditions
- Schizophrenia
- Sponsor
- Federal University of Rio Grande do Sul
- Enrollment
- 19
- Locations
- 1
- Primary Endpoint
- Assessment of cardiovascular risk will be realized by measurement of cytokine levels, C-reactive protein and cholesterol levels.
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?
Detailed Description
Randomized, double-blind, placebo-controlled trial comparing supplementation with resveratrol or placebo in patients diagnosed with schizophrenia.
Investigators
Karine Zortéa
Master
Federal University of Rio Grande do Sul
Eligibility Criteria
Inclusion Criteria
- •Men 18-65 years old, diagnosed with schizophrenia according to DSM-IV and ICD-10, which are in clozapine medication for at least 6 months.
Exclusion Criteria
- •Patients will be excluded from the study:
- •Have a diagnosis of diabetes
- •Use other antipsychotic drugs, clozapine beyond
- •Using medicines for diabetes or dyslipidaemia
- •Accept not participate in any stage of the research.
Arms & Interventions
resveratrol
Intervention: resveratrol
corn starch
(10 patients) 100mg 2x/day 1 month
Intervention: resveratrol
Outcomes
Primary Outcomes
Assessment of cardiovascular risk will be realized by measurement of cytokine levels, C-reactive protein and cholesterol levels.
Time Frame: 1 month
Assessment of cardiovascular risk will be realized by measurement of cytokine levels (IL-12p70, IL-6, IL-10, IL-1b, IL-8 and TNF-α), C-reactive protein and cholesterol levels (total cholesterol, LDL, HDL, triglycerides) in patients with schizophrenia before and after supplementation with resveratrol or placebo.
Secondary Outcomes
- Cognitive performance will be assessed with a battery of cognitive tests and BPRS (brief psychiatric rating scale) to assess symptoms.(1 month)